Roche reported a 1% decline in group sales, expressed in Swiss francs, in the first quarter as competition from biosimilar products eroded demand for the cancer drugs Avastin and Herceptin, and the rheumatoid arthritis drug Rituxan. By contrast, sales of diagnostic products, including tests for both Covid-19 and non-Covid-19 applications, were strong.
